Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 4/20 | 0.59 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.59 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | CPN1 | P15169 | 2/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 2/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21341280 | 1.00 | SLC6A1 (0.59) | SLC6A1SLC6A11SLC6A13TSHRLMNA | |
| SCHEMBL16856684 | 1.00 | SLC6A1 (0.59) | SLC6A1SLC6A11SLC6A13TSHRLMNA | |
| SCHEMBL16359913 | 0.94 | SLC6A1 (0.52) | SLC6A1SLC6A11SLC6A13TSHRLMNA | |
| SCHEMBL25015448 | 0.88 | — | — | |
| SCHEMBL14218506 | 0.88 | — | — | |
| SCHEMBL24073181 | 0.88 | — | — | |
| SCHEMBL7755255 | 0.82 | SLC6A1 (0.61) | SLC6A1SLC6A11SLC6A13TSHRLMNA | |
| SCHEMBL17204414 | 0.81 | SLC6A1 (0.55) | SLC6A1SLC6A11SLC6A13TSHRLMNA | |
| SCHEMBL2880053 | 0.80 | SLC6A1 (0.50) | SLC6A1SLC6A11SLC6A13TSHRLMNA | |
| SCHEMBL3982090 | 0.80 | SLC6A1 (0.59) | SLC6A1SLC6A11SLC6A13TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3255042-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC (KR) | 2020-12-30 | — | — | EP | disclosed |
| US-20200190062-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC. (KR) | 2020-06-18 | — | — | US | disclosed |
| US-10611754-B2 | Heterocyclic compound and pharmaceutical composition comprising same | BEYONDBIO INC. (KR) | 2020-04-07 | — | — | US | disclosed |
| US-10336787-B2 | Progesterone analogs and uses related thereto | EMORY UNIVERSITY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190135786-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC. (KR) | 2019-05-09 | — | — | US | disclosed |
| US-10227328-B2 | Heterocyclic compound and pharmaceutical composition comprising same | BEYONDBIO INC. (KR) | 2019-03-12 | — | — | US | disclosed |
| US-20180273510-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC. (KR) | 2018-09-27 | — | — | US | disclosed |
| US-9132133-B2 | Nitrogen containing compounds | WOCKHARDT LTD. (IN) | 2015-09-15 | — | — | US | disclosed |
| US-20150174133-A1 | NITROGEN CONTAINING COMPOUNDS | WOCKHARDT LIMITED (IN) | 2015-06-25 | — | — | US | disclosed |
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | US | disclosed |
| CN-101679440-A | Pyrrolopyrimidine derivatives as jak3 inhibitors | PALAU PHARMA SA | 2010-03-24 | — | — | CN | disclosed |
| US-20070112000-A1 | Chemical compounds | ASTRAZENECA R&D ALDERLEY (GB) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336787-B2 | Progesterone analogs and uses related thereto | PGR, SHBG, PGRMC1 | SLC6A1 1252/4885SLC6A11 1082/4885SLC6A13 1314/4885 |
| US-20190135786-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CDK5, CDK1, CDK4 | SLC6A1 3063/4885SLC6A11 2667/4885SLC6A13 3418/4885 |
| US-20150174133-A1 | NITROGEN CONTAINING COMPOUNDS | NOS2, NOS1, NCF1 | SLC6A1 1130/4885SLC6A11 1290/4885SLC6A13 1664/4885 |
| US-20070112000-A1 | Chemical compounds | HSD11B1, CYP11B1, HSD11B2 | SLC6A1 1965/4885SLC6A11 1311/4885SLC6A13 2637/4885 |
| US-10227328-B2 | Heterocyclic compound and pharmaceutical composition comprising same | CDK5, CDK1, CDK4 | SLC6A1 3063/4885SLC6A11 2667/4885SLC6A13 3418/4885 |
| US-20200190062-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CDK5, CDK3, CDK1 | SLC6A1 3201/4885SLC6A11 2856/4885SLC6A13 3483/4885 |
| US-20180273510-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CDK5, CDK1, CDK4 | SLC6A1 3063/4885SLC6A11 2667/4885SLC6A13 3418/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SLC6A1 4851/4885SLC6A11 4850/4885SLC6A13 4853/4885 |
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | LSS, ABCG2, SELL | SLC6A1 1832/4885SLC6A11 1824/4885SLC6A13 2322/4885 |
| US-10611754-B2 | Heterocyclic compound and pharmaceutical composition comprising same | CDK5, CDK1, CDK4 | SLC6A1 3063/4885SLC6A11 2667/4885SLC6A13 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.